ERMA — Enorama Pharma AB Cashflow Statement
0.000.00%
- SEK27.52m
- SEK24.49m
- SEK2.74m
Annual cashflow statement for Enorama Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | — | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.9 | -41.5 | -42.1 | -47.5 | -62.8 |
| Depreciation | |||||
| Non-Cash Items | — | — | — | — | 15.6 |
| Unusual Items | |||||
| Changes in Working Capital | -4.61 | 4.97 | -2.77 | -8.6 | -12.6 |
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -30.2 | -33 | -41.3 | -35.7 | -59.3 |
| Capital Expenditures | -1.82 | 0 | 0 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | 0 | 0 | 0 |
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.82 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | -1.79 | -1.57 | 12 | -4.68 | -0.612 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39.5 | 25.3 | 41.9 | 35.3 | 50.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.47 | -8.06 | 2.01 | -4.07 | 0.952 |